Oxford BioMedica (LSE:OXB) Debt-to-Equity : 1.51 (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Oxford BioMedica Debt-to-Equity?

Oxford BioMedica's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £3.65 Mil. Oxford BioMedica's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £107.80 Mil. Oxford BioMedica's Total Stockholders Equity for the quarter that ended in Dec. 2023 was £74.01 Mil. Oxford BioMedica's debt to equity for the quarter that ended in Dec. 2023 was 1.51.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Oxford BioMedica's Debt-to-Equity or its related term are showing as below:

LSE:OXB' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.87 Max: 6
Current: 1.51

During the past 13 years, the highest Debt-to-Equity Ratio of Oxford BioMedica was 6.00. The lowest was 0.04. And the median was 0.87.

LSE:OXB's Debt-to-Equity is ranked worse than
92.7% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs LSE:OXB: 1.51

Oxford BioMedica Debt-to-Equity Historical Data

The historical data trend for Oxford BioMedica's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioMedica Debt-to-Equity Chart

Oxford BioMedica Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.11

0.12

0.05

0.56

1.51

Oxford BioMedica Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.05	0.48	0.56	0.66	1.51

Competitive Comparison of Oxford BioMedica's Debt-to-Equity

For the Biotechnology subindustry, Oxford BioMedica's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxford BioMedica's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioMedica's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Oxford BioMedica's Debt-to-Equity falls into.

Oxford BioMedica Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Oxford BioMedica's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.654	+	107.804)	/	74.006
	=	1.51

Oxford BioMedica's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.654	+	107.804)	/	74.006
	=	1.51

Oxford BioMedica (LSE:OXB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Oxford BioMedica Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Oxford BioMedica's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxford BioMedica (LSE:OXB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioMedica PLC (LSE:OXB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

OXBDF:USA OXBl:UK OXO:Germany

Address

Windrush Court, Transport Way, Oxford, GBR, OX4 6LT

Website

https://www.oxb.com

Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focuses on the field of immunotherapy by managing a platform of technologies for designing gene-based medicines. The company's operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of its revenue from Europe.

Oxford BioMedica (LSE:OXB) Headlines

No Headlines